In addition, clinical studies have clearly shown that an activating mutation of PDGFRB, RAS or KIT cooperates with an existing AML-ETO fusion gene generated by chromosomal translocation in AML patients [2,3]. Here, KIT is linked to acute myeloid leukemia.